US · Healthcare · Biotechnology
EPS came in at 0.51 against a street estimate of -0.34 — a beat of 250.0%.
Analysts rate Apnimed, Inc. Common Stock a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $50.33.
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 APNIMED, INC. – FORM 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash Position: $172.8 million as of June 30, 2026 (up from | 2026-09-08 |
| Results announced · Q3 2026 APNIMED Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Net Income Q2 2026: $125.9 million (vs. net loss of $69.5 million in Q2 2025) • Cash P | 2026-09-08 |
| Charter / bylaws change · Q3 2026 APNIMED, INC. – 8-K FILING SUMMARY HEADLINE NUMBERS • Company completed its initial public offering (IPO) on August 3, 2026 • Stock trades on Nasdaq | 2026-08-03 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Apnimed, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.